{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,23]],"date-time":"2025-12-23T07:34:40Z","timestamp":1766475280395,"version":"3.48.0"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,12,22]]},"DOI":"10.7759\/cureus.99896","type":"journal-article","created":{"date-parts":[[2025,12,23]],"date-time":"2025-12-23T07:32:19Z","timestamp":1766475139000},"source":"Crossref","is-referenced-by-count":0,"title":["Real-World Outcomes of Antiretroviral Therapy in People Living With HIV in Saudi Arabia: A Three-Year Observational Cohort Study From a Tertiary Care Center"],"prefix":"10.7759","author":[{"given":"Ali","family":"Alsaeed","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a006841","article-title":"Origins of HIV and the AIDS pandemic","volume":"1","author":"Sharp PM","year":"2011","unstructured":"Sharp PM, Hahn BH. Origins of HIV and the AIDS pandemic. Cold Spring Harb Perspect Med. 2011, 1:a006841. 10.1101\/cshperspect.a006841","journal-title":"Cold Spring Harb Perspect Med"},{"key":"ref2","article-title":"The Path That Ends AIDS: UNAIDS Global AIDS Update 2023","year":"2023","unstructured":"The Path That Ends AIDS. UNAIDS Global AIDS Update 2023. Joint United Nations Programme on HIV\/AIDS, Geneva; 2023."},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.5334\/aogh.4277","article-title":"Advancing the global fight against HIV\/AIDS: strategies, barriers, and the road to eradication","volume":"89","author":"Kumah E","year":"2023","unstructured":"Kumah E, Boakye DS, Boateng R, Agyei E. Advancing the global fight against HIV\/AIDS: strategies, barriers, and the road to eradication. Ann Glob Health. 2023, 89:83. 10.5334\/aogh.4277","journal-title":"Ann Glob Health"},{"key":"ref4","unstructured":"HIV.gov. Global Statistics. (2025). Accessed. February 2025: http:\/\/HIV.gov."},{"key":"ref5","unstructured":"World Health Organization. HIV and AIDS. key facts. (2025). https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/hiv-aids."},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1007\/s40121-024-01062-6","article-title":"Expanding treatment opportunities: reviewing the current state of injectable antiretrovirals for treatment of HIV","volume":"13","author":"Binkley A","year":"2024","unstructured":"Binkley A, Zimmerman M, Maguire C. Expanding treatment opportunities: reviewing the current state of injectable antiretrovirals for treatment of HIV. Infect Dis Ther. 2024, 13:2475-88. 10.1007\/s40121-024-01062-6","journal-title":"Infect Dis Ther"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/j.jiph.2023.06.012","article-title":"Human immunodeficiency virus in Saudi Arabia: current and future challenges","volume":"16","author":"Al-Mozaini M","year":"2023","unstructured":"Al-Mozaini M, Al-Rahabani T, Dirar Q, et al.. Human immunodeficiency virus in Saudi Arabia: current and future challenges. J Infect Public Health. 2023, 16:1500-9. 10.1016\/j.jiph.2023.06.012","journal-title":"J Infect Public Health"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.2147\/IDR.S270355","article-title":"HIV in the Kingdom of Saudi Arabia: can we change the way we deal with co-infections","volume":"14","author":"Al-Mozaini M","year":"2021","unstructured":"Al-Mozaini M, Alrahbeni T, Dirar Q, Alotibi J, Alrajhi A. HIV in the Kingdom of Saudi Arabia: can we change the way we deal with co-infections. Infect Drug Resist. 2021, 14:111-7. 10.2147\/IDR.S270355","journal-title":"Infect Drug Resist"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1080\/09540121.2015.1074653","article-title":"Lifelong antiretroviral therapy or HIV cure: the benefits for the individual patient","volume":"28","author":"Buell KG","year":"2016","unstructured":"Buell KG, Chung C, Chaudhry Z, Puri A, Nawab K, Ravindran RP. Lifelong antiretroviral therapy or HIV cure: the benefits for the individual patient. AIDS Care. 2016, 28:242-6. 10.1080\/09540121.2015.1074653","journal-title":"AIDS Care"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1007\/s11904-014-0229-5","article-title":"Optimizing ART adherence: update for HIV treatment and prevention","volume":"11","author":"Robbins RN","year":"2014","unstructured":"Robbins RN, Spector AY, Mellins CA, Remien RH. Optimizing ART adherence: update for HIV treatment and prevention. Curr HIV\/AIDS Rep. 2014, 11:423-33. 10.1007\/s11904-014-0229-5","journal-title":"Curr HIV\/AIDS Rep"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.2147\/PPA.S192735","article-title":"Adherence to HIV treatment regimens: systematic literature review and meta-analysis","volume":"13","author":"Altice F","year":"2019","unstructured":"Altice F, Evuarherhe O, Shina S, Carter G, Beaubrun AC. Adherence to HIV treatment regimens: systematic literature review and meta-analysis. Patient Prefer Adherence. 2019, 13:475-90. 10.2147\/PPA.S192735","journal-title":"Patient Prefer Adherence"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-025-56116-1","article-title":"Time to HIV viral rebound and frequency of post-treatment control after analytical interruption of antiretroviral therapy: an individual data-based meta-analysis of 24 prospective studies","volume":"16","author":"Gunst JD","year":"2025","unstructured":"Gunst JD, Gohil J, Li JZ, et al.. Time to HIV viral rebound and frequency of post-treatment control after analytical interruption of antiretroviral therapy: an individual data-based meta-analysis of 24 prospective studies. Nat Commun. 2025, 16:906. 10.1038\/s41467-025-56116-1","journal-title":"Nat Commun"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1098\/rspb.2005.3352","article-title":"Adherence to antiretroviral HIV drugs: how many doses can you miss before resistance emerges?","volume":"273","author":"Smith RJ","year":"2006","unstructured":"Smith RJ. Adherence to antiretroviral HIV drugs: how many doses can you miss before resistance emerges?. Proc Biol Sci. 2006, 273:617-24. 10.1098\/rspb.2005.3352","journal-title":"Proc Biol Sci"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1005000","article-title":"HIV reactivation from latency after treatment interruption occurs on average every 5-8 days--implications for HIV remission","volume":"11","author":"Pinkevych M","year":"2015","unstructured":"Pinkevych M, Cromer D, Tolstrup M, et al.. HIV reactivation from latency after treatment interruption occurs on average every 5-8 days--implications for HIV remission. PLoS Pathog. 2015, 11:e1005000. 10.1371\/journal.ppat.1005000","journal-title":"PLoS Pathog"},{"key":"ref15","unstructured":"The Saudi AIDS National Program (NAP). Saudi guidelines for HIV treatment. (2024). https.\/\/www.moh.gov.sa\/Ministry\/MediaCenter\/Publications\/Pages\/HIV-GUIDELINES.pdf."},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1016\/j.virol.2024.110362","article-title":"30 years of HIV therapy: current and future antiviral drug targets","volume":"603","author":"Nuwagaba J","year":"2025","unstructured":"Nuwagaba J, Li JA, Ngo B, Sutton RE. 30 years of HIV therapy: current and future antiviral drug targets. Virology. 2025, 603:110362. 10.1016\/j.virol.2024.110362","journal-title":"Virology"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1128\/CMR.00102-15","article-title":"Approved antiviral drugs over the past 50 years","volume":"29","author":"De Clercq E","year":"2016","unstructured":"De Clercq E, Li G. Approved antiviral drugs over the past 50 years. Clin Microbiol Rev. 2016, 29:695-747. 10.1128\/CMR.00102-15","journal-title":"Clin Microbiol Rev"},{"key":"ref18","article-title":"HIV antiretroviral therapy","author":"Kemnic TR","year":"2025","unstructured":"Kemnic TR, Gulick PG. HIV antiretroviral therapy. StatPearls [Internet]. StatPearls Publishing, Treasure Island (FL); 2025."},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0081355","article-title":"Closing the gap: increases in life expectancy among treated HIV-positive individuals in the United States and Canada","volume":"8","author":"Samji H","year":"2013","unstructured":"Samji H, Cescon A, Hogg RS, et al.. Closing the gap: increases in life expectancy among treated HIV-positive individuals in the United States and Canada. PLoS One. 2013, 8:e81355. 10.1371\/journal.pone.0081355","journal-title":"PLoS One"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(24)00219-6","article-title":"The continuing challenge of infectious diseases","volume":"24","author":"Keddy KH","year":"2024","unstructured":"Keddy KH, Gobena T. The continuing challenge of infectious diseases. Lancet Infect Dis. 2024, 24:800-1. 10.1016\/S1473-3099(24)00219-6","journal-title":"Lancet Infect Dis"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofaa456","article-title":"Burden of disease in PWH harboring a multidrug-resistant virus: data from the PRESTIGIO Registry","volume":"7","author":"Galli L","year":"2020","unstructured":"Galli L, Parisi MR, Poli A, et al.. Burden of disease in PWH harboring a multidrug-resistant virus: data from the PRESTIGIO Registry. Open Forum Infect Dis. 2020, 7:ofaa456. 10.1093\/ofid\/ofaa456","journal-title":"Open Forum Infect Dis"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1016\/S2666-5247(20)30006-9","article-title":"Pan-resistant HIV-1 emergence in the era of integrase strand-transfer inhibitors: a case report","volume":"1","author":"Puertas MC","year":"2020","unstructured":"Puertas MC, Ploumidis G, Ploumidis M, et al.. Pan-resistant HIV-1 emergence in the era of integrase strand-transfer inhibitors: a case report. Lancet Microbe. 2020, 1:130-5. 10.1016\/S2666-5247(20)30006-9","journal-title":"Lancet Microbe"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2023.1133407","article-title":"Strategies to overcome HIV drug resistance-current and future perspectives","volume":"14","author":"Temereanca A","year":"2023","unstructured":"Temereanca A, Ruta S. Strategies to overcome HIV drug resistance-current and future perspectives. Front Microbiol. 2023, 14:1133407. 10.3389\/fmicb.2023.1133407","journal-title":"Front Microbiol"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1186\/s12981-025-00763-3","article-title":"Insights into medication adherence among HIV-positive patients: the integrated change model","volume":"22","author":"Mirzaei-Alavijeh M","year":"2025","unstructured":"Mirzaei-Alavijeh M, Rahimi F, Hamzeh B, Mansouri F, Shoukohi N, Jalilian F. Insights into medication adherence among HIV-positive patients: the integrated change model. AIDS Res Ther. 2025, 22:66. 10.1186\/s12981-025-00763-3","journal-title":"AIDS Res Ther"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkn020","article-title":"Forgiveness of non-adherence to HIV-1 antiretroviral therapy","volume":"61","author":"Shuter J","year":"2008","unstructured":"Shuter J. Forgiveness of non-adherence to HIV-1 antiretroviral therapy. J Antimicrob Chemother. 2008, 61:769-73. 10.1093\/jac\/dkn020","journal-title":"J Antimicrob Chemother"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-146-8-200704170-00007","article-title":"Adherence to nonnucleoside reverse transcriptase inhibitor-based HIV therapy and virologic outcomes","volume":"146","author":"Nachega JB","year":"2007","unstructured":"Nachega JB, Hislop M, Dowdy DW, Chaisson RE, Regensberg L, Maartens G. Adherence to nonnucleoside reverse transcriptase inhibitor-based HIV therapy and virologic outcomes. Ann Intern Med. 2007, 146:564-73. 10.7326\/0003-4819-146-8-200704170-00007","journal-title":"Ann Intern Med"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkl386","article-title":"Explaining variability in the relationship between antiretroviral adherence and HIV mutation accumulation","volume":"58","author":"Braithwaite RS","year":"2006","unstructured":"Braithwaite RS, Shechter S, Roberts MS, Schaefer A, Bangsberg DR, Harrigan PR, Justice AC. Explaining variability in the relationship between antiretroviral adherence and HIV mutation accumulation. J Antimicrob Chemother. 2006, 58:1036-43. 10.1093\/jac\/dkl386","journal-title":"J Antimicrob Chemother"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3018(21)00322-2","article-title":"Forgiveness of an intermittent HIV treatment strategy","volume":"9","author":"Parienti JJ","year":"2022","unstructured":"Parienti JJ, Haberer JE. Forgiveness of an intermittent HIV treatment strategy. Lancet HIV. 2022, 9:68-9. 10.1016\/S2352-3018(21)00322-2","journal-title":"Lancet HIV"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1136\/sextrans-2024-056202","article-title":"B\/F\/TAF forgiveness to non-adherence","volume":"100","author":"Maggiolo F","year":"2024","unstructured":"Maggiolo F, Taramasso L, Valenti D, Blanchi S, Centorrino F, Comi L, Di Biagio A. B\/F\/TAF forgiveness to non-adherence. Sex Transm Infect. 2024, 100:418-22. 10.1136\/sextrans-2024-056202","journal-title":"Sex Transm Infect"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpharm.2024.125157","article-title":"An updated overview on long-acting therapeutics for the prevention and treatment of human immunodeficiency virus (HIV) from a perspective of pharmaceutics","volume":"670","author":"Dinh L","year":"2025","unstructured":"Dinh L, Blackard JT, Robertson J, et al.. An updated overview on long-acting therapeutics for the prevention and treatment of human immunodeficiency virus (HIV) from a perspective of pharmaceutics. Int J Pharm. 2025, 670:125157. 10.1016\/j.ijpharm.2024.125157","journal-title":"Int J Pharm"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1080\/17425247.2020.1783233","article-title":"Long-acting approaches for delivery of antiretroviral drugs for prevention and treatment of HIV: a review of recent research","volume":"17","author":"Cobb DA","year":"2020","unstructured":"Cobb DA, Smith NA, Edagwa BJ, McMillan JM. Long-acting approaches for delivery of antiretroviral drugs for prevention and treatment of HIV: a review of recent research. Expert Opin Drug Deliv. 2020, 17:1227-38. 10.1080\/17425247.2020.1783233","journal-title":"Expert Opin Drug Deliv"},{"key":"ref32","article-title":"Advancements in HIV treatment: the impact of antiretroviral therapy on patient health and quality of life","volume":"15","author":"Landon J","year":"2024","unstructured":"Landon J. Advancements in HIV treatment: the impact of antiretroviral therapy on patient health and quality of life. J AIDS Clin Res. 2024, 15:","journal-title":"J AIDS Clin Res"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-133-1-200007040-00004","article-title":"Adherence to protease inhibitor therapy and outcomes in patients with HIV infection","volume":"133","author":"Paterson DL","year":"2000","unstructured":"Paterson DL, Swindells S, Mohr J, et al.. Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Ann Intern Med. 2000, 133:21-30. 10.7326\/0003-4819-133-1-200007040-00004","journal-title":"Ann Intern Med"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.1186\/s12913-015-0846-8","article-title":"Strengthening adherence to anti retroviral therapy (ART) monitoring and support: operation research to identify barriers and facilitators in Nepal","volume":"15","author":"Bam K","year":"2015","unstructured":"Bam K, Rajbhandari RM, Karmacharya DB, Dixit SM. Strengthening adherence to anti retroviral therapy (ART) monitoring and support: operation research to identify barriers and facilitators in Nepal. BMC Health Serv Res. 2015, 15:188. 10.1186\/s12913-015-0846-8","journal-title":"BMC Health Serv Res"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.1097\/00126334-200202011-00002","article-title":"Addressing the challenges of adherence","volume":"29 Suppl 1","author":"Bartlett JA","year":"2002","unstructured":"Bartlett JA. Addressing the challenges of adherence. J Acquir Immune Defic Syndr. 2002, 29 Suppl 1:S2-10. 10.1097\/00126334-200202011-00002","journal-title":"J Acquir Immune Defic Syndr"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.1007\/s11908-999-0049-8","article-title":"Medication adherence among HIV-infected patients: understanding the complex behavior of patients taking this complex therapy","volume":"1","author":"Cheever LW","year":"1999","unstructured":"Cheever LW, Wu AW. Medication adherence among HIV-infected patients: understanding the complex behavior of patients taking this complex therapy. Curr Infect Dis Rep. 1999, 1:401-7. 10.1007\/s11908-999-0049-8","journal-title":"Curr Infect Dis Rep"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.1186\/s12977-022-00608-1","article-title":"A clinical review of HIV integrase strand transfer inhibitors (INSTIs) for the prevention and treatment of HIV-1 infection","volume":"19","author":"Zhao AV","year":"2022","unstructured":"Zhao AV, Crutchley RD, Guduru RC, Ton K, Lam T, Min AC. A clinical review of HIV integrase strand transfer inhibitors (INSTIs) for the prevention and treatment of HIV-1 infection. Retrovirology. 2022, 19:22. 10.1186\/s12977-022-00608-1","journal-title":"Retrovirology"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.1111\/hiv.13593","article-title":"Twelve-month effectiveness and safety of bictegravir\/emtricitabine\/tenofovir alafenamide in people with HIV: real-world insights from BICSTaR cohorts","volume":"25","author":"Esser S","year":"2024","unstructured":"Esser S, Brunetta J, Inciarte A, et al.. Twelve-month effectiveness and safety of bictegravir\/emtricitabine\/tenofovir alafenamide in people with HIV: real-world insights from BICSTaR cohorts. HIV Med. 2024, 25:440-53. 10.1111\/hiv.13593","journal-title":"HIV Med"},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.1086\/426595","article-title":"Similar adherence rates favor different virologic outcomes for patients treated with nonnucleoside analogues or protease inhibitors","volume":"40","author":"Maggiolo F","year":"2005","unstructured":"Maggiolo F, Ravasio L, Ripamonti D, et al.. Similar adherence rates favor different virologic outcomes for patients treated with nonnucleoside analogues or protease inhibitors. Clin Infect Dis. 2005, 40:158-63. 10.1086\/426595","journal-title":"Clin Infect Dis"},{"key":"ref40","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0b013e318050d8c2","article-title":"HIV-infected patients receiving lopinavir\/ritonavir-based antiretroviral therapy achieve high rates of virologic suppression despite adherence rates less than 95%","volume":"45","author":"Shuter J","year":"2007","unstructured":"Shuter J, Sarlo JA, Kanmaz TJ, Rode RA, Zingman BS. HIV-infected patients receiving lopinavir\/ritonavir-based antiretroviral therapy achieve high rates of virologic suppression despite adherence rates less than 95%. J Acquir Immune Defic Syndr. 2007, 45:4-8. 10.1097\/QAI.0b013e318050d8c2","journal-title":"J Acquir Immune Defic Syndr"},{"key":"ref41","doi-asserted-by":"publisher","DOI":"10.1086\/507526","article-title":"Less than 95% adherence to nonnucleoside reverse-transcriptase inhibitor therapy can lead to viral suppression","volume":"43","author":"Bangsberg DR","year":"2006","unstructured":"Bangsberg DR. Less than 95% adherence to nonnucleoside reverse-transcriptase inhibitor therapy can lead to viral suppression. Clin Infect Dis. 2006, 43:939-41. 10.1086\/507526","journal-title":"Clin Infect Dis"},{"key":"ref42","doi-asserted-by":"publisher","DOI":"10.1310\/98b3-pwg8-pmyw-w5bp","article-title":"Simpler regimens may enhance adherence to antiretrovirals in HIV-infected patients","volume":"3","author":"Maggiolo F","year":"2002","unstructured":"Maggiolo F, Ripamonti D, Arici C, et al.. Simpler regimens may enhance adherence to antiretrovirals in HIV-infected patients. HIV Clin Trials. 2002, 3:371-8. 10.1310\/98b3-pwg8-pmyw-w5bp","journal-title":"HIV Clin Trials"},{"key":"ref43","doi-asserted-by":"publisher","DOI":"10.1093\/jalm\/jfaa176","article-title":"Limits of detection and limits of infection: quantitative HIV measurement in the era of U = U","volume":"6","author":"Weld ED","year":"2021","unstructured":"Weld ED. Limits of detection and limits of infection: quantitative HIV measurement in the era of U = U. J Appl Lab Med. 2021, 6:324-6. 10.1093\/jalm\/jfaa176","journal-title":"J Appl Lab Med"},{"key":"ref44","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)30418-0","article-title":"Risk of HIV transmission through condomless sex in serodifferent gay couples with the HIV-positive partner taking suppressive antiretroviral therapy (PARTNER): final results of a multicentre, prospective, observational study","volume":"393","author":"Rodger AJ","year":"2019","unstructured":"Rodger AJ, Cambiano V, Bruun T, et al.. Risk of HIV transmission through condomless sex in serodifferent gay couples with the HIV-positive partner taking suppressive antiretroviral therapy (PARTNER): final results of a multicentre, prospective, observational study. Lancet. 2019, 393:2428-38. 10.1016\/S0140-6736(19)30418-0","journal-title":"Lancet"},{"key":"ref45","doi-asserted-by":"publisher","DOI":"10.1503\/cmaj.180311","article-title":"Risk of sexual transmission of human immunodeficiency virus with antiretroviral therapy, suppressed viral load and condom use: a systematic review","volume":"190","author":"LeMessurier J","year":"2018","unstructured":"LeMessurier J, Traversy G, Varsaneux O, et al.. Risk of sexual transmission of human immunodeficiency virus with antiretroviral therapy, suppressed viral load and condom use: a systematic review. CMAJ. 2018, 190:E1350-60. 10.1503\/cmaj.180311","journal-title":"CMAJ"},{"key":"ref46","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2018.21167","article-title":"HIV viral load and transmissibility of HIV infection: undetectable equals untransmittable","volume":"321","author":"Eisinger RW","year":"2019","unstructured":"Eisinger RW, Dieffenbach CW, Fauci AS. HIV viral load and transmissibility of HIV infection: undetectable equals untransmittable. JAMA. 2019, 321:451-2. 10.1001\/jama.2018.21167","journal-title":"JAMA"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/441421-real-world-outcomes-of-antiretroviral-therapy-in-people-living-with-hiv-in-saudi-arabia-a-three-year-observational-cohort-study-from-a-tertiary-care-center","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,23]],"date-time":"2025-12-23T07:32:23Z","timestamp":1766475143000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/441421-real-world-outcomes-of-antiretroviral-therapy-in-people-living-with-hiv-in-saudi-arabia-a-three-year-observational-cohort-study-from-a-tertiary-care-center"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,22]]},"references-count":46,"URL":"https:\/\/doi.org\/10.7759\/cureus.99896","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12,22]]}}}